Best of 2021 ASCO & EHA

Page 1


Thank you to our sponsors!

2


Virtual ASCO 2021 Total ASCO abstracts for 2021 = 4,782 Myeloma Abstracts = 282  Oral = 26  Poster Discussion = 32  Poster Session = 106  Publication Only = 118 3


Abstracts Overview 1. Immune Therapies • CAR-T • Bispecifics 2. Frontline Therapy • Triplets • Quadruplets 4


Abstracts Overview 3. Monitoring • Mass spectrometry • Imaging 4. Relapsed therapies • Ninlaro®(ixazomib) • Xpovio®(selinexor) 5


Immune Therapies

6


Abstract #8005: CARTITUDE-1

https://www.myeloma.org/videos/ciltacabtagene-autoleucel-bcma-directed-cart-therapy-relapsed-refractory-multiple-myeloma-cartitude1

7


CARTITUDE-1 Update • • • • •

Median follow-up – 18 months Overall response rate = 98% (!) sCR = 80% Response duration = 66% at 18 months Some newer concerns about delayed toxicities and how to mitigate. 8


Idecabtagene vicleucel (ide-cel, bb2121) •

Idecabtagene vicleucel (ide-cel, bb2121), a BCMA-directed CAR T cell therapy, inrelapsed and refractory multiple myeloma: Updated KarMMa results

https://www.myeloma.org/videos/idecabtagene-vicleucel-ide-cel-bb2121-bcma-directed-car-t-cell-therapyrelapsed-refractory

Characteristics of neurotoxicity associated with idecabtagene vicleucel (ide-cel, bb2121)in patients with relapsed and refractory multiple myeloma (RRMM) in the pivotal phase II myeloma KarMMa study

https://www.myeloma.org/videos/characteristics-neurotoxicity-associated-idecabtagene-vicleucel-patientsrelapsed-refractory

Idecabtagene Vicleucel (Ide-cel, bb2121), a BCMA-Directed CAR T Cell Therapy, in Patients With Relapsed andRefractory Multiple Myeloma: Updated KarMMa Results

https://www.myeloma.org/videos/idecabtagene-vicleucel-relapsed-refractory-myeloma-patients-karmma

KarMMa-4: Idecabtagene vicleucel (ide-cel, bb2121), a BCMA-directed CAR T-celltherapy in high-risk newly diagnosed multiple myeloma

https://www.myeloma.org/videos/karmma-4-idecabtagene-vicleucel-bcma-directed-car-t-cell-therapy-high-risknewly-diagnosed

9


Abstract #8007 - teclistamab

https://www.myeloma.org/videos/updated-phase-1-teclistamab-trial-results-relasped-refractory-multiple-myeloma

10


Teclistamab Update • 40 patients • Response rate = 65% • Of responders: • VGPR = 58% • CR/ sCR = 30% • Toxicities acceptable/ manageable for this bispecific 11


Abstract #8006: elranatamab

https://www.myeloma.org/videos/efficacy-safety-elranatamab-bcma-cd3-bispecific-antibody-patients-relapsed-or-refractory

12


What’s next for CAR T? • Rollout of approved products • Earlier use

• Next generation CARs 13


Where will bi-specifics fit in? • Ongoing IV/ SC • Course of therapy – 6 months?

• Toxicity concerns persist? 14


Audience Q&A Type and submit your questions here. Click the Q&A icon circled below if you have minimized the “Ask Question” window.


Triplets and Quadruplets

16


EHA Late Breaking Abstract

https://www.myeloma.org/videos/overall-survival-results-daratumumab-lenalidomide-dexamethasone-transplant-ineligible-MAIA

17


Progression Free Survival (PFS) data 60-month PFS rate

% surviving without progression

100 80 52.5%

60

D-Rd: median, NR 28.7%

40

Rd: median, 34.4 months 20

HR, 0.53; 95% CI, 0.43-0.66; P <0.0001

0 0 3 6 9 12 15 18 21 24 27 30 33 36 39 42 45 48 51 54 57 60 63 66 69 Months No. at risk Rd 369 333 307 280 255 237 220 205 196 179 172 155 146 133 123 113 105 94 63 36 12 4 D-Rd 368 347 335 320 309 300 290 276 266 256 246 237 232 222 210 199 195 170 123 87 51 17

2 5

0 0

• D-Rd continued to demonstrate a significant PFS benefit, with median PFS not reached with D-Rd • These data provide a new PFS benchmark in patients with NDMM who are transplant ineligible

18


Overall Survival (OS) data 60-month OS rate 100

% surviving

80

66.3% D-Rd: median, NR

53.1%

60

Rd: median, NR 40 20

HR, 0.68; 95% CI, 0.53-0.86; P = 0.0013

0 0 3 6 9 12 15 18 21 24 27 30 33 36 39 42 45 48 51 54 57 60 63 66 69 72 Months No. at risk Rd 369 351 343 336 324 317 308 300 294 281 270 258 251 241 232 223 213 183 134 85 42 14 5 D-Rd 368 350 346 344 338 334 328 316 305 302 297 286 280 273 266 255 249 228 170 118 63 22 6

1 1

0 0

D-Rd demonstrated a significant benefit in OS, with a 32% reduction in the risk of death, in patients with NDMM who are transplant ineligible 19


Abstract #8004: CASSIOPEIA Part II

https://www.myeloma.org/videos/daratumumab-maintenance-or-observation-after-treatment-vtd-asct-patients-cassiopeia

20


CASSIOPEIA Update Key Point • Dara maintenance – no added benefit with Dara VTd induction/ consolidation

• Does this change thinking about Dara maintenance? 21


Audience Q&A Type and submit your questions here. Click the Q&A icon circled below if you have minimized the “Ask Question” window.


Monitoring

23


Abstract #8009: STAMINA Trial

MASS-FIX versus standard methods to predict for PFS and OS among multiple myeloma patients participating on the STAMINA trial. https://meetinglibrary.asco.org/record/196625/abstract

Angela Dispenzieri Mayo Clinic Rochester, MN, USA

24


MASS-FIX Testing in STAMINA Trial • MASS-FIX excellent independent predictor of PFS and OS • Compared with MRD Testing with NGF * Promising use of simple blood testing 25


Abstract #8010: GEM (Spanish) Trial

Analysis of minimal residual disease in bone marrow by NGF and in peripheral blood by mass spectrometry in newly diagnosed multiple myeloma patients enrolled in the GEM2012MENOS65 clinical trial.

Noemi Puig University of Salamanca Salamanca, Spain

https://meetinglibrary.asco.org/record/195522/abstract

26


Mass spectrometry in GEM (Spanish) Trial • Mass Spec and MRD by NGF found to be complementary in assessing outcomes • Patterns of NGF +/- and Mass Spec +/being further studied 27


Abstract #8012

https://www.myeloma.org/videos/prospective-comparison-whole-body-mri-fdg-pet-ct-detection-multiple-myeloma-correlation

28


Key questions about imaging • Is WBLDCT (Whole Body Low Dose CT) the standard? • What about PET/CT versus MRI?

29


Audience Q&A Type and submit your questions here. Click the Q&A icon circled below if you have minimized the “Ask Question” window.


Relapsed Therapies

31


Ninlaro®(ixazomib)

32


Abstract EP963

https://www.myeloma.org/videos/final-analysis-phase-3-tourmaline-mm1-study-investigating-ixazomib-lenalidomide

33


Abstract S184

https://www.myeloma.org/videos/mrd-evaluation-during-ixazomib-maintenance-newly-diagnosed-myeloma-tourmaline

34


Significant PFS benefit with ixazomib vs placebo in patients converting from MRD+ to MRD– status 1.0

Censored

MRD+ to MRD–

n

Events

24month PFS, %

Median PFS, months

Ixazomib

42

2

97.5

NE

Placebo

18

5

80.1

NE

Ixazomib, MRD+ to MRD–

Probability of PFS

0.8

0.6

HR 0.139, 95% CI 0.026–0.733, p=0.007

Placebo, MRD+ to MRD–

0.4

• There was no significant difference in PFS between ixazomib and placebo among patients with sustained MRD– status

0.2

0.0 0 3 Number of patients at risk Ixazomib, MRD– to MRD– Ixazomib, MRD+ to MRD– Placebo, MRD– to MRD– Placebo, MRD+ to MRD–

6

9

12

15

18 21 24 27 30 Months since randomization

33

36

39

42

45

48

75

72

71

71

69

65

63

57

52

38

28

22

16

3

1

0

0

42

41

41

41

41

40

38

34

32

28

20

11

6

3

2

0

0

43

43

43

42

41

41

38

35

35

24

17

15

5

2

0

0

0

18

16

16

16

16

15

13

13

11

9

6

4

2

0

0

0

0


Xpovio®(selinexor)

36


Abstract #8018: STOMP Trial

Oral selinexor, pomalidomide, and dexamethasone (XPd) at recommended phase 2 dose in relapsed refractory multiple myeloma (MM). https://meetinglibrary.asco.org/record/195449/abstract

Darrell White, MD Dalhousie University Halifax, NS, Canada

37


Abstract #8038: Selinexor + Kd

https://www.myeloma.org/videos/once-weekly-selinexor-carfilzomib-dexamethasone-xkd-heavily-pretreated-multiple-myeloma

38


Abstract #8024: Selinexor + Vd

https://www.myeloma.org/videos/effects-refractory-status-to-revlimid-to-either-XVd-or-Vd-myeloma-treatment-boston-trial

39


Abstract #8019: BOSTON Study

Survival among older patients with previously treated multiple myeloma treated with selinexor, bortezomib, and dexamethasone (XVd) in the BOSTON study. https://meetinglibrary.asco.org/record/195458/abstract

Prof. Thierry Facon, MD Université of Lille, CHU Lille, Service des Maladies du Sang, Lille, France

40


Selinexor in Elderly: Update • Patients over age 65 years • Excellent results with selinexor + Vd (BOSTON regimen) re: efficacy/ toxicity • Both PFS and OS improved 41


Abstract #8027

Effects of weekly selinexor, bortezomib, dexamethasone (XVd) versus standard twice weekly bortezomib and dexamethasone (Vd) on RASmutated previously treated multiple myeloma (MM). https://meetinglibrary.asco.org/record/195493/abstract

42


Audience Q&A Type and submit your questions here. Click the Q&A icon circled below if you have minimized the “Ask Question” window.


Key questions from IMWG Summit • Several items already discussed • Additional points: • Diagnosis/ treatment for HR/ ultra HR SMM (2/20/20 system) • Immune therapy registry and virtual biobank 44


Key questions from IMWG Summit • Additional points: • Role of new MoAbs and new agents (ex. CelMods) • COVID-19 vaccination

45


Additional IMF Resources Acronyms & Abbreviations: https://imf-d8-prod.s3.us-west-1.wasabisys.com/2021-03/acronymand-abbrev-3-2021.pdf

Myeloma Terms & Definitions: https://issuu.com/international-myeloma-foundation/docs/myelomaterms-definitions

46


Webinar Replay and Slides

As follow up to today's workshop, we will have the speaker slides and a video replay available. These will be provided to you shortly after the workshop concludes.


Feedback Survey Please take a moment to complete the survey. It will also be emailed to you shortly after the workshop.

Survey Click Here to complete the feedback survey


Audience Q&A Type and submit your questions here. Click the Q&A icon circled below if you have minimized the “Ask Question” window.


Thank you to our sponsors!

50



Turn static files into dynamic content formats.

Create a flipbook
Issuu converts static files into: digital portfolios, online yearbooks, online catalogs, digital photo albums and more. Sign up and create your flipbook.